Notice under section 708A(5)(e) of the Corporations Act

Emyria Limited ("Issuer") notifies ASX (as the operator of the prescribed financial market on which the securities identified below are or are to be quoted) under section 708A(5)(e) of the Corporations Act that:

1. the securities identified below were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

2. as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and with section 674 of the Corporations Act; and

3. it is in discussions with a consultant in relation to a possible executive Director role. Other than this matter, as at the date of this notice, there is no excluded information of the type referred to in sub-sections 708A(7) and 708A(8) of the Corporations Act.

DETAILS OF THE SECURITIES ISSUED	
Class of Securities:	Ordinary Shares
ASX Code of the Securities:	EMD
Date of the issue of securities:	24 November 2021
Total number of Shares issued:	20,000,000

Release authorised by The Board of Directors of the Company.

For further information on Emyria, please contact:

Dr. Michael Winlo
Managing Director
1300 436 363
mwinlo@emyria.com

Lexi O'Halloran
Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

Andrew Williams
Media Relations
+61 (0) 412 614 125
andreww@profilemedia.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.

Emyria's Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.